Skip to main content
D&D Pharmatech Inc. logo

D&D Pharmatech Inc. — Investor Relations & Filings

Ticker · 347850 ISIN · KR7347850000 KO Manufacturing
Open in API
Filings indexed 109 across all filing types
Latest filing 2024-04-25 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 347850

About D&D Pharmatech Inc.

http://www.ddpharmatech.com/

D&D Pharmatech is a clinical-stage biopharmaceutical company specializing in the development of therapies based on GLP-1 (Glucagon-like peptide-1) and related peptides. The company's pipeline primarily targets metabolic diseases, including obesity and MASH (Metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative disorders. A core competency is its proprietary oral peptide delivery technology. Key candidates in its portfolio include DD01, an injectable dual GLP-1/glucagon receptor agonist for MASH that has received FDA Fast Track Designation, and an oral GLP-1 therapy for obesity. The company operates a global model, funding drug development through specialized subsidiaries, with research functions in Korea and clinical development managed by its US-based team.

Recent filings

Filing Released Lang Actions
증권발행실적보고서
Share Issue/Capital Change Classification · 1% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed with the Financial Supervisory Service (FSS) in South Korea. It details the final results of a public offering, including subscription and allocation data, share issuance amounts, and the use of proceeds. This document is a standard regulatory filing required after a capital raise (IPO) to report the actual issuance results, which falls under the 'Share Issue/Capital Change' category.
2024-04-25 Korean
[발행조건확정]증권신고서(지분증권)
Capital/Financing Update Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고서' (Securities Registration Statement Amendment) filed with the Financial Services Commission (금융위원회) in South Korea. It details the finalization of the offering price (공모가액 확정) for D&D Pharmatech's IPO. This type of regulatory filing, which updates the terms of a securities offering, falls under the 'Regulatory Filings' category as it is a formal legal document submitted to a regulatory body to update previously filed information.
2024-04-19 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 1% confidence The document is a '정정신고서' (Amended Registration Statement) for an '투자설명서' (Prospectus) filed by D&D Pharmatech. It details changes to the public offering price, total offering amount, and allocation ratios for institutional and general investors. In the context of financial filings, an amended prospectus related to an IPO or public offering is classified as a regulatory filing that provides updated terms for the offering.
2024-04-19 Korean
투자설명서
Capital/Financing Update Classification · 1% confidence The document is a '투자설명서' (Investment Prospectus) for D&D Pharmatech, detailing a public offering of shares (1,100,000 shares) with specific pricing, subscription periods, and regulatory disclosures required by the Financial Supervisory Service (FSS) in South Korea. It includes sections on investment risks, business overview, and legal disclaimers typical of a formal securities registration statement/prospectus. In the provided taxonomy, this document type is best classified as a Regulatory Filing (RNS) as it serves as a formal, legally required disclosure document for a public offering that does not fit into the specific categories like 10-K or Annual Report.
2024-04-17 Korean
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by D&D Pharmatech. This document is a formal regulatory filing required for public offerings, detailing amendments to risk factors, financial projections, and business descriptions. In the context of financial document classification, such registration statements and their amendments are categorized as Regulatory Filings (RNS) as they do not fit into the specific categories of annual reports, earnings releases, or proxy statements.
2024-04-16 Korean
[기재정정]증권신고서(지분증권)
Regulatory Filings Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by D&D Pharmatech. It details amendments to a previously submitted securities registration statement, specifically adding information regarding technology transfer contracts and risk factors. This is a formal regulatory filing submitted to the Financial Supervisory Service (FSS) in South Korea, which falls under the category of regulatory filings.
2024-04-16 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.